Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2008;102:e73-e85
Published online before print April 3, 2008, doi: 10.1161/CIRCRESAHA.108.174367
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
102/8/e73    most recent
CIRCRESAHA.108.174367v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chung, A. W.Y.
Right arrow Articles by van Breemen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chung, A. W.Y.
Right arrow Articles by van Breemen, C.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Primary prevention
Right arrow Animal models of human disease
Right arrow Other Vascular biology
(Circulation Research. 2008;102:e73.)
© 2008 American Heart Association, Inc.


UltraRapid Communications

Long-Term Doxycycline Is More Effective Than Atenolol to Prevent Thoracic Aortic Aneurysm in Marfan Syndrome Through the Inhibition of Matrix Metalloproteinase-2 and -9

Ada W.Y. Chung, H. H. Clarice Yang, Marek W. Radomski, Cornelis van Breemen

From the Child and Family Research Institute (A.W.Y.C., H.H.C.Y., C.V.B.), Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada; and School of Pharmacy and Pharmaceutical Sciences (M.W.R.), Trinity College, Dublin, Ireland.

Correspondence to Ada W.Y. Chung, PhD, Cardiovascular Science, Room 2099, 950 28th W Ave, Vancouver, British Columbia, Canada V5Z 4H4. E-mail achung{at}mrl.ubc.ca

β-Blockers, eg, atenolol, are the cornerstone therapy for thoracic aortic aneurysm (TAA) in patients with Marfan syndrome; however, continued aortic dilatation has been reported. We have demonstrated that matrix metalloproteinase (MMP)-2 and -9 were upregulated during progression of TAA in Marfan syndrome, accompanied with degenerated elastic fibers and vasomotor dysfunction. We hypothesized that doxycycline, a nonspecific inhibitor of MMPs, would ameliorate TAA by attenuating elastic fiber degeneration and improving vasomotor function. A well-characterized mouse model of Marfan syndrome (Fbn1C1039G/+) was used. Mice were untreated (n=40), given doxycycline (0.24g/L, n=30), or given atenolol (0.5g/L, n=30) in drinking water at 6 weeks of age. The Fbn1+/+ mice served as control (n=40). At 3, 6, and 9 months, aortic segments from the ascending, arch, and descending portions were used to obtain the "average" value of the whole thoracic aorta. TAA was prevented in the doxycycline group, whereas mild aneurysm was evident in the atenolol group. Doxycycline improved elastic fiber integrity, normalized aortic stiffness, and prevented vessel weakening. The impairment of vasocontraction and endothelium-dependent relaxation in the untreated and atenolol groups were improved by doxycycline. The upregulation of transforming growth factor-β in the Marfan aorta was suppressed by doxycycline. Doxycycline augmented expression ratios of tissue inhibitors of MMP to MMPs. Intraperitoneally injected neutralizing antibodies against MMP-2 and -9 yielded similar effects to doxycycline. We concluded that long-term treatment with doxycycline, through the inhibition of MMP-2 and -9, is more effective than atenolol in preventing TAA in Marfan syndrome by preserving elastic fiber integrity, normalizing vasomotor function, and reducing transforming growth factor-β activation.


Key Words: doxycycline • atenolol • thoracic aortic aneurysm • Marfan syndrome • matrix metalloproteinase




This article has been cited by other articles:


Home page
CirculationHome page
C. Pilop, F. Aregger, R. C. Gorman, R. Brunisholz, B. Gerrits, T. Schaffner, J. H. Gorman III, G. Matyas, T. Carrel, and B. M. Frey
Proteomic Analysis in Aortic Media of Patients With Marfan Syndrome Reveals Increased Activity of Calpain 2 in Aortic Aneurysms
Circulation, September 15, 2009; 120(11): 983 - 991.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. W.Y. Chung, H.H. C. Yang, J. M. Kim, M. K. Sigrist, E. Chum, W. A. Gourlay, and A. Levin
Upregulation of Matrix Metalloproteinase-2 in the Arterial Vasculature Contributes to Stiffening and Vasomotor Dysfunction in Patients With Chronic Kidney Disease
Circulation, September 1, 2009; 120(9): 792 - 801.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Matt, F. Schoenhoff, J. Habashi, T. Holm, C. Van Erp, D. Loch, O. D. Carlson, B. F. Griswold, Q. Fu, J. De Backer, et al.
Circulating Transforming Growth Factor-{beta} in Marfan Syndrome
Circulation, August 11, 2009; 120(6): 526 - 532.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. C. Braverman
Transforming Growth Factor-{beta}: A Biomarker in Marfan Syndrome?
Circulation, August 11, 2009; 120(6): 464 - 466.
[Full Text] [PDF]


Home page
Am J Sports MedHome page
L. V. Gulotta, J. R. Rudzki, D. Kovacevic, C. C. T. Chen, D. Milentijevic, and R. J. Williams III
Chondrocyte Death and Cartilage Degradation After Autologous Osteochondral Transplantation Surgery in a Rabbit Model
Am. J. Sports Med., July 1, 2009; 37(7): 1324 - 1333.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Ramirez and H. C. Dietz
Extracellular Microfibrils in Vertebrate Development and Disease Processes
J. Biol. Chem., May 29, 2009; 284(22): 14677 - 14681.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Carta, S. Smaldone, L. Zilberberg, D. Loch, H. C. Dietz, D. B. Rifkin, and F. Ramirez
p38 MAPK Is an Early Determinant of Promiscuous Smad2/3 Signaling in the Aortas of Fibrillin-1 (Fbn1)-null Mice
J. Biol. Chem., February 27, 2009; 284(9): 5630 - 5636.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
R. E Pyeritz
Marfan syndrome: 30 years of research equals 30 years of additional life expectancy
Heart, February 1, 2009; 95(3): 173 - 175.
[Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. West, J. Harral, K. Lane, Y. Deng, B. Ickes, D. Crona, S. Albu, D. Stewart, and K. Fagan
Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions
Am J Physiol Lung Cell Mol Physiol, November 1, 2008; 295(5): L744 - L755.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. A. Ahimastos, A. M. Dart, B. A. Kingwell, S. A. Jimenez, J. Rosenbloom, F. S. van Dijk, H. Meijers-Heijboer, G. Pals, B. S. Brooke, and H. C. Dietz III
Angiotensin II Blockade in Marfan's Syndrome
N. Engl. J. Med., October 16, 2008; 359(16): 1732 - 1734.
[Full Text] [PDF]